Clinical Trials

Inclusion Criteria:

• Diagnosis of castrate resistant prostate cancer based on standard of clinical care definitions either beginning or receiving standard of care treatments for castrate resistant disease including docetaxel chemotherapy; abiraterone acetate; prednisone;  enzalutamide; immunotherapy; cabazitaxel or mitoxantrone  chemotherapy or radium-223.
• Diagnosis of metastatic kidney cancer based on standard of clinical care definitions either beginning or receiving standard of care treatments for metastatic kidney cancer including VEGF inhibition; biotherapy; immunotherapy or m-TOR inhibitors.
• Willing to learn to perform a finger prick daily for six days and to be able to use a mail-in Federal Express/UPS kit for shipment.

Exclusion Criteria:

• Unwilling to perform a finger prick for blood draw or unable to follow directions
• Bleeding tendencies (known hemophilia; bleeding diathesis, etc)
• On anti-coagulation using Coumadin; heparin, direct thrombin inhibitors (or similar) medications as part of standard clinical care (aspirin, Plavix like medications or other non-steroidal medication use is not an exclusion factor).